1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Industry organizations on October 25 called for simplifying the regulatory procedures associated with software as a medical device (SaMD) and strengthening the review system for such products in Japan. The calls were made at an industry hearing held by the…
To read the full story
Related Article
- Regulatory Reform Panel Urges Better Trial Environment, SaMD Review
December 24, 2021
- Public-Private Collaboration Needed to Refine SaMD Regulatory System
November 26, 2021
- Deregulation Panel Prods Govt to Fuel SaMD Development
June 3, 2021
REGULATORY
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
- Japan Grants Orphan Tags to Atrasentan, Efzimfotase, and Lots More
March 3, 2025
- Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
March 3, 2025
- Japan Extends Re-Examination Period for Zeposia, Lupkynis
March 3, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…